Navigation Links
Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinson's
Date:2/18/2010

German-American consortium to test nicotine patch in 150 PD patients

NEW YORK, Feb. 18 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation announced that it has awarded $1.1 million for an international clinical trial vetting the potential of a nicotine skin patch to modify the progression of Parkinson's disease. The funding was made under the Clinical Intervention Awards initiative, one of MJFF's Edmond J. Safra Core Programs for PD Research.

This first-ever multisite, investigator-initiated collaboration between Parkinson's study groups in Germany and the United States will encompass a one-year double-blind, placebo-controlled trial in 150 newly diagnosed Parkinson's patients. Principal investigators Wolfgang H. Oertel and Marcus M. Unger of Philipps University Marburg, Germany, and Karl Kieburtz of the University of Rochester, New York, will evaluate the disease-modifying potential of transdermal nicotine using standard skin patches of the type used by millions of smokers as a quitting aid. The production of the patches being used in this trial has been supported by the pharmaceutical company Novartis.

While scientists have previously studied the symptomatic effects of nicotine in Parkinson's patients, this is the first long-term clinical trial expressly designed to test whether nicotine may in fact modify the progression of PD. Parkinson's researchers have long been intrigued by epidemiological research showing a possible link between cigarette smoking and a lowered risk of PD: the disease is far less prevalent among smokers compared to never-smokers. Nicotine also has demonstrated beneficial effects on PD in pre-clinical studies. Yet key questions about the relationship among smoking, nicotine and Parkinson's — including whether smoking tobacco products in fact confers protection and, if so, whether this protection stems from the nicotine in those products — remain unanswered.

Until this trial provides data on the safety profile of transdermal nicotine in never-smokers, the study leaders caution that patients should not introduce nicotine into their treatment regimen without the explicit recommendation of their doctor. The benefits of transdermal nicotine for PD have not yet been conclusively proven, and its safety for use in people who have never smoked remains unestablished. Trial participants will be closely monitored for any adverse health effects that may occur as a result of nicotine treatment.

The commercialization of a therapy capable of retarding or stopping the progression of Parkinson's disease — rather than merely masking symptoms while the underlying disease continues to worsen — would be a transformative event in the lives of the estimated 5 million Parkinson's patients worldwide. Transdermal nicotine holds the additional advantages of wide availability and relatively low cost.

As with all MJFF awards, continued funding is dependent on researchers' achieving predetermined milestones. Progress and outcome reports will be posted to the Foundation's Web site as they become available.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded almost $176 million in research to date. 

SOURCE Michael J. Fox Foundation


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... ... 2017 , ... The Brian Gifford Agency, an Indiana-based firm providing asset protection ... Campagna Academy in a charity drive to provide for at-risk children and teens in ... Academy is a nonprofit organization that has offered critical programs to at-risk and foster ...
(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body of ... its product now available through Jet.com. , After 25 years of development, the ... is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having ...
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... faith they shared to overcome struggles in life. “Our Mountains to Climb: A Journey ... Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences drive ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... , August 17, 2017 DarioHealth ... Company with mobile health and big data solutions, ... agreements with domestic and non-U.S. investors for the ... and shares of the Company,s newly designated Series ... offerings. The Company expects to conduct a closing ...
(Date:8/15/2017)... HOUSTON , Aug. 15, 2017   Mostyn Law ... in Houston, Texas . The Mostyn Law ... the past 2 years. That is why Mostyn Law ... Texas to show its appreciation. Blood supplies ... to fall 5% short of hospital needs in August. That is ...
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
Breaking Medicine Technology: